City

Clinical trials near Fukuoka, Japan

Active studies with a listed research site in Fukuoka, Japan.

10active studies

4recruiting now

19countries represented

112largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity, Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil61 locations

AmgenSponsor

Updated 2026-08-04 · NCT07225686See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

Orforglipron, DulaglutideTreatment

Belgium, Brazil71 locations

Eli Lilly and CompanySponsor

Updated 2026-08-19 · NCT07668336See eligibility →

Opening soonPhase 1

A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Japan3 locations

Eli Lilly and CompanySponsor

Updated 2026-08-14 · NCT07765511See eligibility →

Active, not recruitingPhase 1, Phase 2

A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

Overweight and ObesityCondition

AZD9550, placeboTreatment

Austria, Canada15 locations

AstraZenecaSponsor

Updated 2026-08-26 · NCT06151964See eligibility →

Active, not recruitingPhase 1

A Study of LY3971297 in Healthy Participants

Healthy, ObesityCondition

LY3971297, PlaceboTreatment

Japan, Singapore7 locations

Eli Lilly and CompanySponsor

Updated 2026-07-16 · NCT06148272See eligibility →

Active, not recruitingNot applicable

Special Use - Results Surveillance on Long-term Use With Wegovy®

ObesityCondition

SemaglutideTreatment

Japan112 locations

Novo Nordisk A/SSponsor

Updated 2026-04-22 · NCT06283667See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease

Obesity DiseaseCondition

Maridebart cafraglutide, PlaceboTreatment

Japan30 locations

AmgenSponsor

Updated 2025-12-17 · NCT06987695See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Fukuoka, Japan

Current studies

Related cities